MaxCyte, Inc. (NASDAQ:MXCT) EVP Sells $79,003.47 in Stock

MaxCyte, Inc. (NASDAQ:MXCTGet Rating) EVP Thomas M. Ross sold 14,133 shares of the business’s stock in a transaction that occurred on Monday, December 5th. The stock was sold at an average price of $5.59, for a total transaction of $79,003.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thomas M. Ross also recently made the following trade(s):

  • On Friday, December 2nd, Thomas M. Ross sold 15,000 shares of MaxCyte stock. The stock was sold at an average price of $6.02, for a total transaction of $90,300.00.
  • On Tuesday, November 1st, Thomas M. Ross sold 23,429 shares of MaxCyte stock. The stock was sold at an average price of $6.94, for a total transaction of $162,597.26.
  • On Tuesday, October 11th, Thomas M. Ross sold 4,282 shares of MaxCyte stock. The shares were sold at an average price of $6.51, for a total transaction of $27,875.82.

MaxCyte Trading Up 3.3 %

Shares of MXCT opened at $5.61 on Friday. MaxCyte, Inc. has a 52 week low of $3.36 and a 52 week high of $11.49. The firm’s 50-day simple moving average is $6.41 and its 200 day simple moving average is $5.60.

Analyst Ratings Changes

Separately, BTIG Research cut their price objective on shares of MaxCyte to $9.00 in a research report on Tuesday, November 15th.

Institutional Trading of MaxCyte

Several large investors have recently made changes to their positions in MXCT. Salem Investment Counselors Inc. bought a new position in MaxCyte in the 3rd quarter valued at approximately $25,000. Quantbot Technologies LP acquired a new stake in MaxCyte in the second quarter worth $27,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of MaxCyte during the second quarter valued at about $76,000. PDT Partners LLC acquired a new position in shares of MaxCyte during the second quarter valued at about $76,000. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of MaxCyte by 17.8% during the third quarter. Cubist Systematic Strategies LLC now owns 13,258 shares of the company’s stock valued at $86,000 after buying an additional 2,001 shares during the last quarter. Institutional investors and hedge funds own 66.40% of the company’s stock.

About MaxCyte

(Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

See Also

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.